Today’s BioBrief covers a Phase 3 obesity readout, a major chronic hepatitis B regulatory update, and a large genetic medicine platform deal. We also look at Scancell’s melanoma vaccine signal and zipalertinib’s FDA review in EGFR exon 20 lung cancer.

1. Boehringer Ingelheim / Zealand Pharma — survodutide
   • Mechanism: dual glucagon / GLP-1 receptor agonist
   • Indication: obesity or overweight without type 2 diabetes
   • Stage: Phase 3
   • Key result: 16.6% mean weight loss at 76 weeks versus 3.2% on placebo in 725 adults
   • Why it matters: validates survodutide as a credible late-stage obesity contender, with potential differentiation through its glucagon component
2. GSK / Ionis — bepirovirsen
   • Mechanism: antisense oligonucleotide targeting hepatitis B viral RNA
   • Indication: chronic hepa ...